{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:42:21Z","timestamp":1791078141003,"version":"4.1.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple myeloma (MM) is characterized by the production of monoclonal immunoglobulin and is associated with suppressed uninvolved immunoglobulins and dysfunctional T-cell responses. The biologic basis of this dysfunction remains ill defined. Because T regulatory (Treg) cells play an important role in suppressing normal immune responses, we evaluated the potential role of Treg cells in immune dysfunction in MM. We observed a significant increase in CD4+CD25+ T cells in patients with monoclonal gammopathy of undetermined significance (MGUS) and in patients with MM compared with healthy donors (25% and 26%, respectively, vs 14%); however, Treg cells as measured by FOXP3 expression are significantly decreased in patients with MGUS and MM compared with healthy donors. Moreover, even when they are added in higher proportions, Treg cells in patients with MM and MGUS are unable to suppress anti-CD3\u2013mediated T-cell proliferation. This decreased number and function of Treg cells in MGUS and in MM may account, at least in part, for the nonspecific increase in CD4+CD25+ T cells, thereby contributing to dysfunctional T-cell responses.<\/jats:p>","DOI":"10.1182\/blood-2005-08-3101","type":"journal-article","created":{"date-parts":[[2005,9,9]],"date-time":"2005-09-09T00:43:51Z","timestamp":1126226631000},"page":"301-304","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":207,"title":["Dysfunctional T regulatory cells in multiple myeloma"],"prefix":"10.1182","volume":"107","author":[{"given":"Rao H.","family":"Prabhala","sequence":"first","affiliation":[{"name":"From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of \u201cMagna Gr\u00e6cia\u201d and Cancer Center, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Neri","sequence":"additional","affiliation":[{"name":"From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of \u201cMagna Gr\u00e6cia\u201d and Cancer Center, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooeun E.","family":"Bae","sequence":"additional","affiliation":[{"name":"From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of \u201cMagna Gr\u00e6cia\u201d and Cancer Center, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[{"name":"From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of \u201cMagna Gr\u00e6cia\u201d and Cancer Center, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood A.","family":"Shammas","sequence":"additional","affiliation":[{"name":"From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of \u201cMagna Gr\u00e6cia\u201d and Cancer Center, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles K.","family":"Allam","sequence":"additional","affiliation":[{"name":"From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of \u201cMagna Gr\u00e6cia\u201d and Cancer Center, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Daley","sequence":"additional","affiliation":[{"name":"From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of \u201cMagna Gr\u00e6cia\u201d and Cancer Center, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharminder","family":"Chauhan","sequence":"additional","affiliation":[{"name":"From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of \u201cMagna Gr\u00e6cia\u201d and Cancer Center, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Blanchard","sequence":"additional","affiliation":[{"name":"From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of \u201cMagna Gr\u00e6cia\u201d and Cancer Center, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant S.","family":"Thatte","sequence":"additional","affiliation":[{"name":"From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of \u201cMagna Gr\u00e6cia\u201d and Cancer Center, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of \u201cMagna Gr\u00e6cia\u201d and Cancer Center, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of \u201cMagna Gr\u00e6cia\u201d and Cancer Center, Catanzaro, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111704384480100_REF1","doi-asserted-by":"crossref","unstructured":"Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3: 253-257.","DOI":"10.1038\/nri1032"},{"key":"2019111704384480100_REF2","doi-asserted-by":"crossref","unstructured":"Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6: 345-352.","DOI":"10.1038\/ni1178"},{"key":"2019111704384480100_REF3","doi-asserted-by":"crossref","unstructured":"Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol. 2005;6: 353-360.","DOI":"10.1038\/ni1181"},{"key":"2019111704384480100_REF4","doi-asserted-by":"crossref","unstructured":"Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 2005;6: 331-337.","DOI":"10.1038\/ni1179"},{"key":"2019111704384480100_REF5","doi-asserted-by":"crossref","unstructured":"von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005;6: 338-344.","DOI":"10.1038\/ni1180"},{"key":"2019111704384480100_REF6","doi-asserted-by":"crossref","unstructured":"Munshi NC. Immunoregulatory mechanisms in multiple myeloma. Hematol Oncol Clin North Am. 1997;11: 51-69.","DOI":"10.1016\/S0889-8588(05)70415-9"},{"key":"2019111704384480100_REF7","doi-asserted-by":"crossref","unstructured":"Massaia M, Bianchi A, Attisano C, et al. Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3\/TCR complex [see comments]. Blood. 1991;78: 1770-1780.","DOI":"10.1182\/blood.V78.7.1770.1770"},{"key":"2019111704384480100_REF8","doi-asserted-by":"crossref","unstructured":"Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7\u20131) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 2001;98: 2992-2998.","DOI":"10.1182\/blood.V98.10.2992"},{"key":"2019111704384480100_REF9","doi-asserted-by":"crossref","unstructured":"Xie J, Wang Y, Freeman ME 3rd, Barlogie B, Yi Q. Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood. 2003;101: 4005-4012.","DOI":"10.1182\/blood-2002-11-3368"},{"key":"2019111704384480100_REF10","doi-asserted-by":"crossref","unstructured":"LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103: 1787-1790.","DOI":"10.1182\/blood-2003-02-0361"},{"key":"2019111704384480100_REF11","doi-asserted-by":"crossref","unstructured":"Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001;193: 1303-1310.","DOI":"10.1084\/jem.193.11.1303"},{"key":"2019111704384480100_REF12","doi-asserted-by":"crossref","unstructured":"Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol. 2000;18: 423-449.","DOI":"10.1146\/annurev.immunol.18.1.423"},{"key":"2019111704384480100_REF13","doi-asserted-by":"crossref","unstructured":"Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299: 1057-1061.","DOI":"10.1126\/science.1079490"},{"key":"2019111704384480100_REF14","doi-asserted-by":"crossref","unstructured":"Pagnucco G, Cardinale G, Gervasi F. Targeting multiple myeloma cells and their bone marrow microenvironment. Ann N Y Acad Sci. 2004;1028: 390-399.","DOI":"10.1196\/annals.1322.047"},{"key":"2019111704384480100_REF15","doi-asserted-by":"crossref","unstructured":"Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104: 607-618.","DOI":"10.1182\/blood-2004-01-0037"},{"key":"2019111704384480100_REF16","doi-asserted-by":"crossref","unstructured":"Doganci A, Eigenbrod T, Krug N, et al. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest. 2005;115: 313-325.","DOI":"10.1172\/JCI200522433"},{"key":"2019111704384480100_REF17","doi-asserted-by":"crossref","unstructured":"Huber S, Schramm C, Lehr HA, et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol. 2004;173: 6526-6531.","DOI":"10.4049\/jimmunol.173.11.6526"},{"key":"2019111704384480100_REF18","doi-asserted-by":"crossref","unstructured":"Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986;163: 1037-1050.","DOI":"10.1084\/jem.163.5.1037"},{"key":"2019111704384480100_REF19","doi-asserted-by":"crossref","unstructured":"Baecher-Allan C, Hafler DA. Suppressor T cells in human diseases. J Exp Med. 2004;200: 273-276.","DOI":"10.1084\/jem.20040812"},{"key":"2019111704384480100_REF20","doi-asserted-by":"crossref","unstructured":"Zielinski CE, Jacob SN, Bouzahzah F, Ehrlich BE, Craft J. Naive CD4+ T cells from lupus-prone Fas-intact MRL mice display TCR-mediated hyperproliferation due to intrinsic threshold defects in activation. J Immunol. 2005;174: 5100-5109.","DOI":"10.4049\/jimmunol.174.8.5100"},{"key":"2019111704384480100_REF21","unstructured":"Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9: 606-612."},{"key":"2019111704384480100_REF22","unstructured":"Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003;9: 4404-4408."},{"key":"2019111704384480100_REF23","doi-asserted-by":"crossref","unstructured":"Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173: 1444-1453.","DOI":"10.4049\/jimmunol.173.2.1444"},{"key":"2019111704384480100_REF24","doi-asserted-by":"crossref","unstructured":"Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103: 1755-1762.","DOI":"10.1182\/blood-2003-07-2594"},{"key":"2019111704384480100_REF25","doi-asserted-by":"crossref","unstructured":"Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34: 336-344.","DOI":"10.1002\/eji.200324181"},{"key":"2019111704384480100_REF26","doi-asserted-by":"crossref","unstructured":"Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+ CD25high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106: 2018-2025.","DOI":"10.1182\/blood-2005-02-0642"},{"key":"2019111704384480100_REF27","doi-asserted-by":"crossref","unstructured":"Arnulf B, Bengoufa D, Sarfati E, et al. Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study. Arch Intern Med. 2002;162: 464-467.","DOI":"10.1001\/archinte.162.4.464"},{"key":"2019111704384480100_REF28","doi-asserted-by":"crossref","unstructured":"Askling J, Fored M, Baecklund E, et al. Hematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics following TNF-antagonists. Ann Rheum Dis. 2005;64: 1414-1420.","DOI":"10.1136\/ard.2004.033241"},{"key":"2019111704384480100_REF29","doi-asserted-by":"crossref","unstructured":"Gallo G. Renal complications of B cell dyscrasias. N Engl J Med. 1991;324: 1889-1890.","DOI":"10.1056\/NEJM199106273242610"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/1\/301\/1279179\/zh800106000301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/1\/301\/1279179\/zh800106000301.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:38:55Z","timestamp":1573983535000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/1\/301\/21738\/Dysfunctional-T-regulatory-cells-in-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-08-3101","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}